Adhera Therapeutics (ATRX) 10-Q 16 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 13, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Marina Biotech, Inc.
Entity Central Index Key	737,207
Trading Symbol	mrna
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		27,079,340
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash	$ 1,313	$ 1,824
Accounts receivable		500
Prepaid expenses and other current assets	65	192
Total current assets	1,378	2,516
Intangible assets	6,700	6,700
Other assets	45
Total assets	8,123	9,216
Current liabilities:
Accounts payable	759	687
Accrued payroll and employee benefits	326	183
Other accrued liabilities	1,409	1,072
Total current liabilities	2,494	1,942
Fair value liability for price adjustable warrants	3,672	9,225
Fair value of stock to be issued to settle liabilities	12	75
Deferred tax liabilities	2,345	2,345
Total liabilities	$ 8,523	$ 13,587
Commitments and contingencies
Stockholders' deficit:
Preferred Stock Value
Common stock, $0.006 par value; 180,000,000 shares authorized, 25,523,216 and 26,451,237 shares issued and outstanding at December 31, 2014 and September 30, 2015, respectively	$ 159	$ 153
Additional paid-in capital	334,452	333,264
Accumulated deficit	(335,011)	(337,788)
Total stockholders' deficit	(400)	(4,371)
Total liabilities and stockholders' deficit	$ 8,123	$ 9,216
Series C Preferred Stock
Stockholders' deficit:
Preferred Stock Value
Series D Preferred Stock
Stockholders' deficit:
Preferred Stock Value

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000	100,000
Common stock, par value (in dollars per share)	$ 0.006	$ 0.006
Common stock, shares authorized	180,000,000	180,000,000
Common stock, shares issued	26,451,237	25,523,216
Common stock, shares outstanding	26,451,237	25,523,216
Series C Preferred Stock
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,200	1,200
Preferred stock, shares issued	1,110	1,200
Preferred stock, shares outstanding	1,110	1,200
Preferred Stock, Liquidation Preference, Value	$ 5,550
Series D Preferred Stock
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	220	220
Preferred stock, shares issued	220	0
Preferred stock, shares outstanding	220	0
Preferred Stock, Liquidation Preference, Value	$ 1,110

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue:
License and milestone	$ 80		$ 480
Operating expenses:
Research and development	90	$ 173	574	$ 268
General and administrative	1,022	1,434	3,275	2,573
Total operating expenses	1,112	1,607	3,849	2,841
Loss from operations	(1,032)	(1,607)	(3,369)	(2,841)
Other income (expense):
Interest and other expense				(1,007)
Change in fair value liability for price adjustable warrants	2,485	(5,487)	6,128	(6,256)
Change in fair value of stock reserved for issuance to settle liabilities		(48)		(2,503)
Gain (loss) on foreign exchange		(1)		1
Gain on debt extinguishment		1		5
Gain on settled liabilities	6	19	18	321
Total other income (expense), net	2,491	(5,516)	6,146	(9,439)
Net income (loss)	1,459	(7,123)	2,777	(12,280)
Net income (loss) applicable to common stockholders	$ 769	$ (7,123)	$ 2,087	$ (18,280)
Net income (loss) per common share
Basic (in dollars per share)	$ 0.03	$ (0.28)	$ 0.08	$ (0.75)
Diluted (in dollars per share)	$ (0.06)	$ (0.28)	$ (0.12)	$ (0.75)
Shares used in computing net income (loss) per share
Basic (in shares)	26,462	25,668	26,047	24,248
Diluted (in shares)	30,939	25,668	33,484	24,248
Series C Preferred Stock
Other income (expense):
Deemed dividend related to discount on beneficial conversion feature in convertible preferred shares				$ (6,000)
Series D Preferred Stock
Other income (expense):
Deemed dividend related to discount on beneficial conversion feature in convertible preferred shares	$ (690)		$ (690)

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating activities:
Net income (loss)	$ 2,777	$ (12,280)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Non-cash gain on debt extinguishment		(5)
Non-cash interest expense		1,007
Non-cash license expense	132
Non-cash gain on settlement of liabilities	(18)	(321)
Share-based compensation expense	412	260
Gain on foreign exchange transactions		(1)
Changes in fair market value of liabilities
Stock reserved for issuance to settle liabilities		2,503
Price adjustable warrants	(6,128)	6,256
Cash changes in assets and liabilities
Accounts receivable	500	5
Prepaid expenses and other assets	82	73
Accounts payable	90	(361)
Accrued and other liabilities	546	(501)
Accrued restructuring		(12)
Net cash used in operating activities	(1,607)	(3,377)
Financing activities:
Cash payments of notes payable		(250)
Insurance financing		(8)
Proceeds from exercise of warrants for common stock	1
Net cash provided by financing activities	1,096	5,671
Net increase (decrease) in cash	(511)	2,294
Cash - Beginning of period	1,824	909
Cash - End of period	1,313	3,203
Non-cash financing activities:
Reclassification of fair value liability for price adjustable warrants exercised		1,916
Issuance of common stock to settle liabilities	195	3,517
Fair value of warrants issued to purchase common stock to settle liabilities	65
Debt conversion to common stock		1,479
Par value of common stock issued upon conversion of Series C convertible preferred stock	4
Supplemental disclosure of cash flow information
Cash paid for interest		83
Series C Preferred Stock
Financing activities:
Proceeds from sales of preferred shares and warrants, net		5,929
Non-cash financing activities:
Proceeds from sales of preferred shares and warrants, net		$ 6,000
Series D Preferred Stock
Financing activities:
Proceeds from sales of preferred shares and warrants, net	1,095
Non-cash financing activities:
Proceeds from sales of preferred shares and warrants, net	$ 690

Business, Liquidity and Summary

Business, Liquidity and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business, Liquidity and Summary of Significant Accounting Policies	Note 1 — Business, Liquidity and Summary of Significant Accounting Policies Business We are a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases. Our pipeline includes CEQ508, a product in clinical development for the treatment of Familial Adenomatous Polyposis (“FAP”), for which we have received Orphan Drug Designation (“ODD”) and Fast Track Designation (“FTD”) from the U.S. Food and Drug Administration (“FDA”), and preclinical programs for the treatment of type 1 myotonic dystrophy (“DM1”) and Duchenne muscular dystrophy (“DMD”). Since 2010, we have strategically acquired/in-licensed and further developed nucleic acid chemistry and delivery-related technologies in order to establish a novel and differentiated drug discovery platform. This platform allows us to distinguish ourselves from others in the nucleic acid therapeutics area in that we are the only company capable of creating a wide variety of therapeutics targeting coding and non-coding RNA via multiple mechanisms of action such as RNA interference (“RNAi”), messenger RNA translational inhibition, exon skipping, microRNA (“miRNA”) replacement, miRNA inhibition, and steric blocking in order to modulate gene expression either up or down depending on the specific mechanism of action. Our goal is to dramatically improve the lives of the patients and families affected by orphan diseases through either our own efforts or those of our collaborators and licensees. Liquidity The accompanying condensed consolidated financial statements have been prepared on the basis that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. At September 30, 2015, we had an accumulated deficit of approximately $335.0 million, $108.9 million of which has been accumulated since we focused on RNA therapeutics in June 2008. To the extent that sufficient funding is available, we will continue to incur losses as we continue our research and development (“R&D”) activities. In addition, we have had and will continue to have negative cash flows from operations. We have funded our losses primarily through the sale of common and preferred stock and warrants, revenue provided from our license agreements and, to a lesser extent, equipment financing facilities and secured loans. In 2014 and 2015, we funded operations with a combination of the issuance of preferred stock and license-related revenues. At September 30, 2015, we had negative working capital of $1.1 million and $1.3 million in cash. Our resumed limited operating activities consume the majority of our cash resources. We believe that our current cash resources will enable us to fund our intended operations through March 2016. Our ability to execute our operating plan beyond March 2016 depends on our ability to obtain additional funding. The volatility in our stock price, as well as market conditions in general, could make it difficult for us to raise capital on favorable terms, or at all. If we fail to obtain additional capital when required, we may have to modify, delay or abandon some or all of our planned activities, or terminate our operations. We are currently pursuing both non-dilutive means of obtaining additional capital, primarily from existing and potential future licenses and partnerships, and dilutive means of obtaining additional capital, primarily through the offering of our equity and debt securities. However, there can be no assurance that we will be successful in such endeavors. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis of Preparation and Summary of Significant Accounting Policies Basis of Preparation principles (“U.S. GAAP”) for complete financial statements. The accompanying unaudited financial information should be read in conjunction with the audited consolidated financial statements, including the notes thereto, as of and for the year ended December 31, 2014, included in our 2014 Annual Report on Form 10-K filed with the SEC. The information furnished in this report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the results for the year ending December 31, 2015 or for any future period. Use of Estimates Fair Value of Financial Instruments We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Our cash is subject to fair value measurement and value is determined by Level 1 inputs. We measure the liability for committed stock issuances with a fixed share number using Level 1 inputs. We measure the liability for price adjustable warrants and certain features embedded in notes using the Black-Scholes option pricing model (“Black-Scholes Model”) under various probability weighted scenarios, using Level 3 inputs. The following tables summarize our liabilities measured at fair value on a recurring basis as of December 31, 2014 and September 30, 2015: Level 1 Level 3 Balance at Quoted prices in Level 2 Significant December 31, active markets for Significant other unobservable (In thousands) 2014 identical assets observable inputs inputs Liabilities: Fair value liability for price adjustable warrants $ 9,225 $ - $ - $ 9,225 Fair value liability for shares to be issued 75 75 - - Total liabilities at fair value $ 9,300 $ 75 $ - $ 9,225 Level 1 Level 3 Balance at Quoted prices in Level 2 Significant September 30, active markets for Significant other unobservable (In thousands) 2015 identical assets observable inputs inputs Liabilities: Fair value liability for price adjustable warrants $ 3,672 $ - $ - $ 3,672 Fair value liability for shares to be issued 12 12 - - Total liabilities at fair value $ 3,684 $ 12 $ - $ 3,672 The following presents activity of the fair value liability of price adjustable warrants determined by Level 3 inputs for the nine months ended September 30, 2015: Weighted average as of each measurement date Fair value liability for price adjustable warrants (in thousands) Exercise Price Stock Price Volatility Contractual life (in years) Risk free rate Balance at December 31, 2014 $ 9,225 $ 0.42 $ 0.95 121 % 3.51 0.90 % Warrant issuance in connection with Series D convertible preferred stock 575 0.40 0.44 97 % 1.19 0.73 % Change in fair value included in statement of operations (6,128 ) - - - - - Balance at September 30, 2015 $ 3,672 $ 0.42 $ 0.53 102 % 2.07 0.57 % Net Income (Loss) per Common Share Three Months Ended September 30, Nine Months Ended September 30, 2014 2015 2014 2015 Stock options outstanding 1,303,504 1,316,106 1,303,504 1,316,106 Warrants 21,210,695 1,236,946 21,210,695 1,236,946 Convertible preferred stock 8,000,000 10,150,000 8,000,000 10,150,000 Total 30,514,199 12,703,052 30,514,199 12,703,052 The following is a reconciliation of basic and diluted net income (loss) per share: Three Months Ended September 30 Nine Months Ended September 30 2014 2015 2014 2015 Net income (loss) – numerator basic $ (7,123 ) $ 769 $ (18,280 ) $ 2,087 Change in fair value liability for price adjustable warrants - (2,485 ) - (6,128 ) Net loss excluding change in fair value liability for price adjustable warrants $ (7,123 ) $ (1,716 ) $ (18,280 ) $ (4,041 ) Weighted average common shares outstanding – denominator basic 25,668 26,462 24,248 26,047 Effect of price adjustable warrants - 4,477 - 7,437 Weighted average dilutive common shares outstanding 25,668 30,939 24,248 33,484 Net income (loss) per common share – basic $ (0.28 ) $ 0.03 $ (0.75 ) $ 0.08 Net loss per common share – diluted $ (0.28 ) $ (0.06 ) $ (0.75 ) $ (0.12 )

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2015
Stockholders' Equity [Abstract]
Stockholders' Equity	Note 2 — Stockholders’ Deficit Preferred Stock In March 2014, we entered into a Securities Purchase Agreement with certain investors pursuant to which we sold 1,200 shares of Series C Preferred, and price adjustable warrants to purchase up to 6.0 million shares of our common stock at an initial exercise price of $0.75 per share, for an aggregate purchase price of $6.0 million. The exercise price of the warrants is subject to reduction in the event of certain dilutive stock issuances at any time while the warrants are outstanding, but not to be reduced below $0.28 per share. Each share of Series C Preferred has a stated value of $5,000 per share and is convertible into shares of common stock at a conversion price of $0.75 per share. The Series C Preferred is initially convertible into an aggregate of 8,000,000 shares of our common stock, subject to certain limitations and adjustments, has no stated dividend rate, is not redeemable and has voting rights on an as-converted basis. To account for the issuance of the Series C Preferred and warrants, we first assessed the terms of the warrants and determined that, due to certain anti-dilution provisions, they should be recorded as derivative liabilities. We determined the fair value of the warrants on the issuance date and recorded a liability of $6.5 million. Since the fair value of the warrants exceeded the total proceeds received of $6.0 million, we recorded a loss of $0.5 million upon issuance, which is included in the change in fair value of price adjustable warrants in the consolidated statements of operations. The discount of $6.0 million on the Series C Preferred resulting from the allocation of the entire proceeds to the warrant was accreted as a dividend on the Series C Preferred through the earliest conversion date, which was immediately. The Series C Preferred dividend of $6.0 million was recorded as both a debit and a credit to additional paid-in capital and as a deemed dividend on the Series C Preferred in determining net loss applicable to common stock holders in the consolidated statements of operations. We incurred $0.07 million of stock issuance costs in conjunction with the Series C Preferred, which were netted against the proceeds. In August 2015, we entered into a Securities Purchase Agreement with certain investors pursuant to which we sold 220 shares of Series D Preferred, and warrants to purchase up to 3.44 million shares of our common stock at an initial exercise price of $0.40 per share, for an aggregate purchase price of $1.1 million. The warrants issued in connection with Series D Preferred contain a “down round” provision whereby the exercise price per share to purchase common stock covered by these warrants is subject to reduction in the event of certain dilutive stock issuances at any time within the two year anniversary of the issuance date, but not to be reduced below $0.28 per share. Each share of Series D Preferred has a stated value of $5,000 per share and is convertible into shares of common stock at a conversion price of $0.40 per share. The Series D Preferred is initially convertible into an aggregate of 2,750,000 shares of our common stock, subject to certain limitations and adjustments, has a 5% stated dividend rate, is not redeemable and has voting rights on an as-converted basis. To account for the issuance of the Series D Preferred and warrants, we first assessed the terms of the warrants and determined that, due to the “down round” provision, they should be recorded as derivative liabilities. We determined the fair value of the warrants on the issuance date and recorded a liability of $0.6 million. We also recorded a discount of $0.6 million on the Series D Preferred resulting from the allocation of proceeds to the warrants. We then determined the effective conversion price of the Series D Preferred which resulted in a beneficial conversion feature of $0.7 million. The beneficial conversion feature was recorded as both a debit and a credit to additional paid-in capital and as a deemed dividend on the Series D Preferred in determining net income applicable to common stock holders in the consolidated statements of operations. We incurred $0.01 million of stock issuance costs in conjunction with the Series D Preferred, which were netted against the proceeds. Common Stock In January 2015, we issued 0.12 million common shares with a value of $0.075 million to Novosom as the equity component owed under our December 2014 license agreement with MiNA Therapeutics. In May 2015, we issued 0.21 million common shares with a value of $0.12 million to Novosom as the equity component owed as a result of an accelerated milestone payment under our December 2011 license agreement with Mirna Therapeutics. In June 2015, an investor converted 90 shares of Series C Preferred into 0.6 million shares of common stock. Warrants From January to September 2015, we issued warrants to purchase up to an aggregate of 0.102 million common shares to a vendor providing scientific and development consulting services to our company. The fair value of these warrants at issuance was $0.065 million of which $0.05 million was accrued at December 31, 2014. The following table summarizes warrant activity during the nine months ended September 30, 2015: Warrant Shares Weighted Average Exercise Price Outstanding, December 31, 2014 21,212,813 $ 1.19 Exercised warrants (2,500 ) 0.28 Warrants issued to vendor 104,315 0.68 Warrants issued to Series D Preferred holders 3,437,500 0.40 Expired warrants (86,345 ) 37.60 Outstanding, September 30, 2015 24,665,783 $ 0.95 Expiring in 2015 199,000 Expiring in 2016 - Expiring in 2017 7,235,622 Expiring thereafter 17,231,161

Stock Incentive Plans

Stock Incentive Plans	9 Months Ended
	Sep. 30, 2015
Stock Incentive Plans [Abstract]
Stock Incentive Plans	Note 3 — Stock Incentive Plans Stock-based Compensation Three months ended September 30, Nine months ended September 30, (In thousands) 2014 2015 2014 2015 Research and development $ 15 $ 5 $ 34 $ 36 General and administrative 131 111 152 376 Total $ 146 $ 116 $ 186 $ 412 Stock Options Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2014 1,084,106 $ 5.52 Options Issued 232,000 $ 0.63 Outstanding September 30, 2015 1,316,106 $ 4.66 Exercisable, September 30, 2015 674,830 $ 8.16 The following table summarizes additional information on our stock options outstanding at September 30, 2015: Options Outstanding Options Exercisable Weighted-Average Remaining Weighted Range of Exercise Number Contractual Life Weighted Average Number Average Prices Outstanding (Years) Exercise Price Exercisable Exercise Price $0.63 - $0.82 252,000 4.25 $ 0.65 126,000 $ 0.65 $0.83 - $1.07 1,019,000 7.75 1.07 504,974 1.07 $1.08 - $2.20 2,500 5.94 2.20 1,250 2.20 $2.21 - $50.00 10,500 2.70 47.60 10,500 47.60 $50.01 - $100.00 10,500 2.70 87.60 10,500 87.60 $100.01 - $200.00 16,000 2.70 141.35 16,000 141.35 $200.01 - $526.40 5,606 2.67 213.63 5,606 213.63 Totals 1,316,106 6.91 $ 4.66 674,830 $ 8.16 Weighted-Average Exercisable Remaining Contractual Life (Years) 5.84 In January 2015, we issued options to purchase 0.15 million shares of our common stock to non-employee members of our board of directors at an exercise price of $0.635 per share as the annual grant to such directors for their service on our board of directors during 2015, and we issued options to purchase 0.08 million shares of our common stock to the members of our scientific advisory board at an exercise price of $0.63 per share as the annual grant to such persons for their service on our scientific advisory board during 2015. At September 30, 2015, we had $0.55 million of total unrecognized compensation expense related to unvested stock options. We expect to recognize this cost over a weighted average period of 1.7 years. At September 30, 2015, the intrinsic value of options outstanding or exercisable was zero as there were no options outstanding with an exercise price less than $0.31, the per share closing market price of our common stock at that date. No options were exercised during the nine months ended September 30, 2015.

Intellectual Property and Colla

Intellectual Property and Collaborative Agreements	9 Months Ended
	Sep. 30, 2015
Intellectual Property and Contractual Agreements [Abstract]
Intellectual Property and Collaborative Agreements	Note 4 — Intellectual Property and Collaborative Agreements Novosom

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 5 — Commitments and Contingencies Contingencies -

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 6 — Subsequent Events As described in note 4, in October 2015 we issued 0.03 million shares of common stock to Novosom. Further, in November 2015 an investor converted 90 shares of Series C Preferred into 0.6 million shares of common stock.

Business, Liquidity and Summa12

Business, Liquidity and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Preparation	Basis of Preparation
Use of Estimates	Use of Estimates
Fair Value of Financial Instruments	Fair Value of Financial Instruments We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Our cash is subject to fair value measurement and value is determined by Level 1 inputs. We measure the liability for committed stock issuances with a fixed share number using Level 1 inputs. We measure the liability for price adjustable warrants and certain features embedded in notes using the Black-Scholes option pricing model (“Black-Scholes Model”) under various probability weighted scenarios, using Level 3 inputs. The following tables summarize our liabilities measured at fair value on a recurring basis as of December 31, 2014 and September 30, 2015: Level 1 Level 3 Balance at Quoted prices in Level 2 Significant December 31, active markets for Significant other unobservable (In thousands) 2014 identical assets observable inputs inputs Liabilities: Fair value liability for price adjustable warrants $ 9,225 $ - $ - $ 9,225 Fair value liability for shares to be issued 75 75 - - Total liabilities at fair value $ 9,300 $ 75 $ - $ 9,225 Level 1 Level 3 Balance at Quoted prices in Level 2 Significant September 30, active markets for Significant other unobservable (In thousands) 2015 identical assets observable inputs inputs Liabilities: Fair value liability for price adjustable warrants $ 3,672 $ - $ - $ 3,672 Fair value liability for shares to be issued 12 12 - - Total liabilities at fair value $ 3,684 $ 12 $ - $ 3,672 The following presents activity of the fair value liability of price adjustable warrants determined by Level 3 inputs for the nine months ended September 30, 2015: Weighted average as of each measurement date Fair value liability for price adjustable warrants (in thousands) Exercise Price Stock Price Volatility Contractual life (in years) Risk free rate Balance at December 31, 2014 $ 9,225 $ 0.42 $ 0.95 121 % 3.51 0.90 % Warrant issuance in connection with Series D convertible preferred stock 575 0.40 0.44 97 % 1.19 0.73 % Change in fair value included in statement of operations (6,128 ) - - - - - Balance at September 30, 2015 $ 3,672 $ 0.42 $ 0.53 102 % 2.07 0.57 %
Net Income (Loss) per Common Share	Net Income (Loss) per Common Share Three Months Ended September 30, Nine Months Ended September 30, 2014 2015 2014 2015 Stock options outstanding 1,303,504 1,316,106 1,303,504 1,316,106 Warrants 21,210,695 1,236,946 21,210,695 1,236,946 Convertible preferred stock 8,000,000 10,150,000 8,000,000 10,150,000 Total 30,514,199 12,703,052 30,514,199 12,703,052 The following is a reconciliation of basic and diluted net income (loss) per share: Three Months Ended September 30 Nine Months Ended September 30 2014 2015 2014 2015 Net income (loss) – numerator basic $ (7,123 ) $ 769 $ (18,280 ) $ 2,087 Change in fair value liability for price adjustable warrants - (2,485 ) - (6,128 ) Net loss excluding change in fair value liability for price adjustable warrants $ (7,123 ) $ (1,716 ) $ (18,280 ) $ (4,041 ) Weighted average common shares outstanding – denominator basic 25,668 26,462 24,248 26,047 Effect of price adjustable warrants - 4,477 - 7,437 Weighted average dilutive common shares outstanding 25,668 30,939 24,248 33,484 Net income (loss) per common share – basic $ (0.28 ) $ 0.03 $ (0.75 ) $ 0.08 Net loss per common share – diluted $ (0.28 ) $ (0.06 ) $ (0.75 ) $ (0.12 )

Business, Liquidity and Summa13

Business, Liquidity and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of liabilities measured at fair value on a recurring basis	Level 1 Level 3 Balance at Quoted prices in Level 2 Significant December 31, active markets for Significant other unobservable (In thousands) 2014 identical assets observable inputs inputs Liabilities: Fair value liability for price adjustable warrants $ 9,225 $ - $ - $ 9,225 Fair value liability for shares to be issued 75 75 - - Total liabilities at fair value $ 9,300 $ 75 $ - $ 9,225 Level 1 Level 3 Balance at Quoted prices in Level 2 Significant September 30, active markets for Significant other unobservable (In thousands) 2015 identical assets observable inputs inputs Liabilities: Fair value liability for price adjustable warrants $ 3,672 $ - $ - $ 3,672 Fair value liability for shares to be issued 12 12 - - Total liabilities at fair value $ 3,684 $ 12 $ - $ 3,672
Schedule of fair value liability of price adjustable warrants determined by Level 3	Weighted average as of each measurement date Fair value liability for price adjustable warrants (in thousands) Exercise Price Stock Price Volatility Contractual life (in years) Risk free rate Balance at December 31, 2014 $ 9,225 $ 0.42 $ 0.95 121 % 3.51 0.90 % Warrant issuance in connection with Series D convertible preferred stock 575 0.40 0.44 97 % 1.19 0.73 % Change in fair value included in statement of operations (6,128 ) - - - - - Balance at September 30, 2015 $ 3,672 $ 0.42 $ 0.53 102 % 2.07 0.57 %
Schedule of anti-dilutive securities	Three Months Ended September 30, Nine Months Ended September 30, 2014 2015 2014 2015 Stock options outstanding 1,303,504 1,316,106 1,303,504 1,316,106 Warrants 21,210,695 1,236,946 21,210,695 1,236,946 Convertible preferred stock 8,000,000 10,150,000 8,000,000 10,150,000 Total 30,514,199 12,703,052 30,514,199 12,703,052
Schedule of reconciliation of basic and diluted net income (loss)	Three Months Ended September 30 Nine Months Ended September 30 2014 2015 2014 2015 Net income (loss) – numerator basic $ (7,123 ) $ 769 $ (18,280 ) $ 2,087 Change in fair value liability for price adjustable warrants - (2,485 ) - (6,128 ) Net loss excluding change in fair value liability for price adjustable warrants $ (7,123 ) $ (1,716 ) $ (18,280 ) $ (4,041 ) Weighted average common shares outstanding – denominator basic 25,668 26,462 24,248 26,047 Effect of price adjustable warrants - 4,477 - 7,437 Weighted average dilutive common shares outstanding 25,668 30,939 24,248 33,484 Net income (loss) per common share – basic $ (0.28 ) $ 0.03 $ (0.75 ) $ 0.08 Net loss per common share – diluted $ (0.28 ) $ (0.06 ) $ (0.75 ) $ (0.12 )

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2015
Stockholders' Equity [Abstract]
Schedule of warrant activity	Warrant Shares Weighted Average Exercise Price Outstanding, December 31, 2014 21,212,813 $ 1.19 Exercised warrants (2,500 ) 0.28 Warrants issued to vendor 104,315 0.68 Warrants issued to Series D Preferred holders 3,437,500 0.40 Expired warrants (86,345 ) 37.60 Outstanding, September 30, 2015 24,665,783 $ 0.95 Expiring in 2015 199,000 Expiring in 2016 - Expiring in 2017 7,235,622 Expiring thereafter 17,231,161

Stock Incentive Plans (Tables)

Stock Incentive Plans (Tables)	9 Months Ended
	Sep. 30, 2015
Stock Incentive Plans [Abstract]
Schedule of stock-based compensation expense	Three months ended September 30, Nine months ended September 30, (In thousands) 2014 2015 2014 2015 Research and development $ 15 $ 5 $ 34 $ 36 General and administrative 131 111 152 376 Total $ 146 $ 116 $ 186 $ 412
Schedule of stock option activity	Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2014 1,084,106 $ 5.52 Options Issued 232,000 $ 0.63 Outstanding September 30, 2015 1,316,106 $ 4.66 Exercisable, September 30, 2015 674,830 $ 8.16
Schedule of summary of additional information on stock options outstanding	Options Outstanding Options Exercisable Weighted-Average Remaining Weighted Range of Exercise Number Contractual Life Weighted Average Number Average Prices Outstanding (Years) Exercise Price Exercisable Exercise Price $0.63 - $0.82 252,000 4.25 $ 0.65 126,000 $ 0.65 $0.83 - $1.07 1,019,000 7.75 1.07 504,974 1.07 $1.08 - $2.20 2,500 5.94 2.20 1,250 2.20 $2.21 - $50.00 10,500 2.70 47.60 10,500 47.60 $50.01 - $100.00 10,500 2.70 87.60 10,500 87.60 $100.01 - $200.00 16,000 2.70 141.35 16,000 141.35 $200.01 - $526.40 5,606 2.67 213.63 5,606 213.63 Totals 1,316,106 6.91 $ 4.66 674,830 $ 8.16 Weighted-Average Exercisable Remaining Contractual Life (Years) 5.84

Business, Liquidity and Summa16

Business, Liquidity and Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Liabilities:
Fair value liability for price adjustable warrants	$ 3,672	$ 9,225
Fair value liability for shares to be issued	12	75
Fair value on recurring basis
Liabilities:
Fair value liability for price adjustable warrants	3,672	9,225
Fair value liability for shares to be issued	12	75
Total liabilities at fair value	$ 3,684	$ 9,300
Fair value on recurring basis | Level 1 Quoted prices in active markets for identical assets
Liabilities:
Fair value liability for price adjustable warrants
Fair value liability for shares to be issued	$ 12	$ 75
Total liabilities at fair value	$ 12	$ 75
Fair value on recurring basis | Level 2 Significant other observable inputs
Liabilities:
Fair value liability for price adjustable warrants
Fair value liability for shares to be issued
Total liabilities at fair value
Fair value on recurring basis | Level 3 Significant unobservable inputs
Liabilities:
Fair value liability for price adjustable warrants	$ 3,672	$ 9,225
Fair value liability for shares to be issued
Total liabilities at fair value	$ 3,672	$ 9,225

Business, Liquidity and Summa17

Business, Liquidity and Summary of Significant Accounting Policies (Details 1) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Fair value liability for price adjustable warrants
Balance at December 31, 2014			$ 9,225
Change in fair value included in Statement of Operations	$ (2,485)		(6,128)
Balance at September 30, 2015	3,672		3,672		$ 9,225
Fair Value Liability For Price Adjustable Warrants | Level 3 Significant unobservable inputs
Fair value liability for price adjustable warrants
Balance at December 31, 2014			9,225
Warrant issuance in connection with Series D convertible preferred stock			575
Change in fair value included in Statement of Operations			(6,128)
Balance at September 30, 2015	$ 3,672		$ 3,672		$ 9,225
Exercise Price
Balance at December 31, 2014			$ 0.42
Warrant issuance in connection with Series D convertible preferred stock Exercise Price			0.40
Balance at September 30, 2015	$ 0.42		0.42		$ 0.42
Stock Price
Balance at December 31, 2014			0.95
Warrant issuance in connection with Series D convertible preferred stock per share			0.44
Balance at September 30, 2015	$ 0.53		$ 0.53		$ 0.95
Volatility
Balance at December 31, 2014			121.00%
Warrant issuance in connection with Series D convertible preferred stock Volatility			97.00%
Balance at September 30, 2015	102.00%		102.00%		121.00%
Contractual life (in years)
Warrant issuance in connection with Series D convertible preferred stock (in years)			1 year 2 months 9 days
Contractual life (in years)			2 years 26 days		3 years 6 months 4 days
Risk free rate
Balance at December 31, 2014			0.90%
Warrant issuance in connection with Series D convertible preferred stock Resk Free Rate			0.73%
Balance at September 30, 2015	0.57%		0.57%		0.90%

Business, Liquidity and Summa18

Business, Liquidity and Summary of Significant Accounting Policies (Details 2) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	12,703,052	30,514,199	12,703,052	30,514,199
Stock options outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	1,316,106	1,303,504	1,316,106	1,303,504
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	1,236,946	21,210,695	1,236,946	21,210,695
Convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	10,150,000	8,000,000	10,150,000	8,000,000

Business, Liquidity and Summa19

Business, Liquidity and Summary of Significant Accounting Policies (Details 3) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net income (loss) - numerator basic	$ 769	$ (7,123)	$ 2,087	$ (18,280)
Change in fair value liability for price adjustable warrants	(2,485)		(6,128)
Net loss excluding change in fair value liability for price adjustable warrants	$ (1,716)	$ (7,123)	$ (4,041)	$ (18,280)
Weighted average common shares outstanding - denominator basic	26,462	25,668	26,047	24,248
Effect of price adjustable warrants	4,477		7,437
Weighted average dilutive common shares outstanding	30,939	25,668	33,484	24,248
Net income (loss) per common share - basic (in dollars per share)	$ 0.03	$ (0.28)	$ 0.08	$ (0.75)
Net loss per common share - diluted (in dollars per share)	$ (0.06)	$ (0.28)	$ (0.12)	$ (0.75)

Business, Liquidity and Summa20

Business, Liquidity and Summary of Significant Accounting Policies (Detail Textuals) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013	Jun. 30, 2008
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (335,011)	$ (337,788)			$ 108,900
Working capital deficit	(1,100)
Cash	$ 1,313	$ 1,824	$ 3,203	$ 909

Stockholders' Equity (Details)

Stockholders' Equity (Details)	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Warrant Shares
Outstanding, December 31, 2014	21,212,813
Number of warrants exercised	(2,500)
Warrants issued to vendor	104,315
Warrants issued to Series D Preferred holders	3,437,500
Expired warrants	(86,345)
Outstanding, September 30, 2015	24,665,783
Weighted average exercise price
Outstanding, December 31, 2014 | $ / shares	$ 1.19
Exercised warrants | $ / shares	0.28
Warrants issued to vendor | $ / shares	0.68
Warrants issued to Series D Preferred holders | $ / shares	0.40
Expired warrants | $ / shares	37.6
Outstanding, September 30, 2015 | $ / shares	$ 0.95
Expiring in 2015	199,000
Expiring in 2016
Expiring in 2017	7,235,622
Expiring thereafter	17,231,161

Stockholders' Equity (Preferred

Stockholders' Equity (Preferred Stock) (Detail Textuals) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		9 Months Ended
	Aug. 31, 2015	Mar. 31, 2014	Sep. 30, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Preferred stock, shares authorized			100,000	100,000
Number of common stock called by warrants	3,440,000	6,000,000
Proceeds from sales of Series C preferred shares and warrants, net		$ 6,000
Exercise price of warrants	$ 0.40	$ 0.75	$ 0.95	$ 1.19
Proceeds to warrant was accreted as a dividend			$ 1
Series A Junior Participating Preferred Stock ("Series A Preferred")
Class of Stock [Line Items]
Shares issued during period			90,000
Series B Preferred Stock ("Series B Preferred")
Class of Stock [Line Items]
Shares issued during period			1,000
Series C Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares authorized			1,200	1,200
Shares issued during period		1,200
Conversion price per dollar of stated value		$ 0.75
Proceeds from sales of Series C preferred shares and warrants, net		$ 6,000
Stated value per share of preferred stock		$ 5,000
Exercise price of warrants		$ 0.28
Shares issued upon conversion		8,000,000
Stock issuance costs			$ 70
Proceeds to warrant was accreted as a dividend			6,000
Deemed dividend recorded to additional paid-in capital			6,000
Derivative Liability			6,500
Amount of loss upon issuance			$ 500
Series D Convertible Preferred Stock (Series D Preferred)
Class of Stock [Line Items]
Preferred stock, shares authorized			220	220
Shares issued during period	220
Conversion price per dollar of stated value	$ 0.40
Proceeds from sales of Series C preferred shares and warrants, net	$ 1,100
Stock issuances anniversary	2 years
Share price not to be reduced below	$ 0.28
Stated value per share of preferred stock	$ 5,000
Shares issued upon conversion	2,750,000
Limitations and adjustments dividend rate	5.00%
Beneficial conversion feature			$ 700
Stock issuance costs			10
Proceeds to warrant was accreted as a dividend			600
Derivative Liability			$ 600

Stockholders' Equity (Common St

Stockholders' Equity (Common Stock) (Detail Textuals 1) - USD ($) $ in Thousands	1 Months Ended		9 Months Ended
	May. 31, 2015	Jan. 31, 2015	Sep. 30, 2015
Series C Preferred Stock
Stockholders Equity Note [Line Items]
Converted Common Stock			90
Value of Converted Common Stock			$ 600
Common stock
Stockholders Equity Note [Line Items]
Number of voting right			one vote
Novosom | December 2014 license agreement with MiNA therapeutics
Stockholders Equity Note [Line Items]
Number of common stock issued for settlement	210,000	120,000
Amount pledged to issue common stock	$ 120	$ 75

Stockholders' Equity (Warrants)

Stockholders' Equity (Warrants) (Detail Textuals 2) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	9 Months Ended		12 Months Ended
	Jan. 31, 2015	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Aug. 31, 2015	Mar. 31, 2014
Stockholders Equity Note [Line Items]
Number of warrants called by common stock					3,440,000	6,000,000
Number of warrants exercised		2,500
Exercise price of warrants		$ 0.95		$ 1.19	$ 0.40	$ 0.75
Fair value of warrants issuance		$ (6,128)	$ 6,256
Warrants
Stockholders Equity Note [Line Items]
Number of warrants exercised	2,500
Exercise price of warrants	$ 0.28
Warrants | Vendor
Stockholders Equity Note [Line Items]
Number of warrants called by common stock		102,000
Fair value of warrants issuance		$ 65		$ 50

Stock Incentive Plans (Stock-Ba

Stock Incentive Plans (Stock-Based Compensation Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 116	$ 146	$ 412	$ 186
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	5	15	36	34
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 111	$ 131	$ 376	$ 152

Stock Incentive Plans (Stock Op

Stock Incentive Plans (Stock Option Activity) (Detail 1)	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Shares
Outstanding, December 31, 2014	1,084,106
Options Issued	232,000
Outstanding September 30, 2015	1,316,106
Exercisable September 30, 2015	674,830
Weighted Average Exercise Price
Outstanding, December 31, 2014 | $ / shares	$ 5.52
Options Issued | $ / shares	0.63
Outstanding September 30, 2015 | $ / shares	4.66
Exercisable September 30, 2015 | $ / shares	$ 8.16

Stock Incentive Plans (Stock 27

Stock Incentive Plans (Stock options outstanding) (Details 2) - $ / shares	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Number Outstanding	1,316,106	1,084,106
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	6 years 10 months 28 days
Options Outstanding, Weighted Average Exercise Price	$ 4.66	$ 5.52
Options Exercisable, Number Exercisable	674,830
Options Exercisable, Weighted Average Exercise Price	$ 8.16
Options Outstanding, Weighted-Average Remaining Contractual Life, Exercisable (Years)	5 years 10 months 2 days
Stock options | $0.63 - $0.82
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	$ 0.63
Upper range of price	$ 0.82
Options Outstanding, Number Outstanding	252,000
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	4 years 3 months
Options Outstanding, Weighted Average Exercise Price	$ 0.65
Options Exercisable, Number Exercisable	126,000
Options Exercisable, Weighted Average Exercise Price	$ 0.65
Stock options | $0.83 - $1.07
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	0.83
Upper range of price	$ 1.07
Options Outstanding, Number Outstanding	1,019,000
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	7 years 9 months
Options Outstanding, Weighted Average Exercise Price	$ 1.07
Options Exercisable, Number Exercisable	504,974
Options Exercisable, Weighted Average Exercise Price	$ 1.07
Stock options | $1.08 - $2.20
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	1.08
Upper range of price	$ 2.20
Options Outstanding, Number Outstanding	2,500
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	5 years 11 months 9 days
Options Outstanding, Weighted Average Exercise Price	$ 2.20
Options Exercisable, Number Exercisable	1,250
Options Exercisable, Weighted Average Exercise Price	$ 2.20
Stock options | $2.21 - $50.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	2.21
Upper range of price	$ 50
Options Outstanding, Number Outstanding	10,500
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	2 years 8 months 12 days
Options Outstanding, Weighted Average Exercise Price	$ 47.60
Options Exercisable, Number Exercisable	10,500
Options Exercisable, Weighted Average Exercise Price	$ 47.60
Stock options | $50.01 - $100.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	50.01
Upper range of price	$ 100
Options Outstanding, Number Outstanding	10,500
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	2 years 8 months 12 days
Options Outstanding, Weighted Average Exercise Price	$ 87.60
Options Exercisable, Number Exercisable	10,500
Options Exercisable, Weighted Average Exercise Price	$ 87.60
Stock options | $100.01 - $200.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	100.01
Upper range of price	$ 200
Options Outstanding, Number Outstanding	16,000
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	2 years 8 months 12 days
Options Outstanding, Weighted Average Exercise Price	$ 141.35
Options Exercisable, Number Exercisable	16,000
Options Exercisable, Weighted Average Exercise Price	$ 141.35
Stock options | $200.01 - $526.40
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	200.01
Upper range of price	$ 526.40
Options Outstanding, Number Outstanding	5,606
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	2 years 8 months 1 day
Options Outstanding, Weighted Average Exercise Price	$ 213.63
Options Exercisable, Number Exercisable	5,606
Options Exercisable, Weighted Average Exercise Price	$ 213.63

Stock Incentive Plans (Detail T

Stock Incentive Plans (Detail Textuals) - $ / shares	1 Months Ended	9 Months Ended
	Jan. 31, 2015	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchase		232,000
Options Issued		$ 0.63
Board of directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchase	150,000
Options Issued	$ 0.635
Scientific advisory board
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchase	80,000
Options Issued	$ 0.63

Stock Incentive Plans (Detail29

Stock Incentive Plans (Detail Textuals 1) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)$ / shares
Stock Incentive Plans [Abstract]
Unrecognized compensation cost related to unvested stock options	$ 550
Unrecognized compensation cost related to unvested stock options, recognition period	1 year 8 months 12 days
Intrinsic value of options outstanding	$ 0
Intrinsic value of options exercisable	$ 0
Options outstanding exercise price | $ / shares	$ 0.31

Intellectual Property and Col30

Intellectual Property and Collaborative Agreements (Detail Textuals) - Novosom - USD ($) shares in Thousands, $ in Thousands	1 Months Ended		9 Months Ended
	May. 31, 2015	Jan. 31, 2015	Sep. 30, 2015
December 2014 license agreement with MiNA therapeutics
Intellectual Property And Collaborative Agreements [Line Items]
Cash payable		$ 80
Number of common stock issued for settlement	210	120
Amount pledged to issue common stock	$ 120	$ 75
December 2011 license agreement with MiNA therapeutics
Intellectual Property And Collaborative Agreements [Line Items]
Shares issued during period			240
Value of share issued during period			$ 130
Common stock has yet to be issued			$ 10
Common stock has yet to be issued			30

Subsequent Events (Detail Textu

Subsequent Events (Detail Textuals) - shares	Oct. 15, 2015	Nov. 16, 2015	Mar. 31, 2014
Series C Preferred Stock
Subsequent Event [Line Items]
Shares issued during period			1,200
Subsequent event | Series C Preferred Stock
Subsequent Event [Line Items]
Number of preferred shares converted to common stock		90
Number of common stock issued in conversion of preferred stock		600,000
Subsequent event | Novosom
Subsequent Event [Line Items]
Shares issued during period	30,000